Barriers to mesalamine adherence in patients with inflammatory bowel disease: A qualitative analysis

Journal of Managed Care Pharmacy

Volumn 20, Issue 3, 2014, Pages 309-314

  Devlen, Jennifer ^a   Beusterien, Kathleen ^b   Yen, Linnette ^c   Ahmed, Awais ^d   Cheifetz, Adam S ^d   Moss, Alan C ^d  

^a ICON PLC   (United Kingdom)

^b Outcomes Research Strategies in Health   (United States)

^c SHIRE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; MESALAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; CROHN DISEASE; DRUG COST; DRUG EFFICACY; ELECTRONIC PRESCRIBING; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INFORMATION PROCESSING; INTERVIEW; MAINTENANCE THERAPY; MALE; PATIENT COMPLIANCE; PILL; QUALITATIVE ANALYSIS; SOCIAL STIGMA; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; YOUNG ADULT;

EID: 84896310544     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.3.309     Document Type: Article

References (38)

1. Kane S.V Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929-33.
2. Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56(12):3463-70.
3. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43.
4. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53(4):1020-24.
5. Moody GA, Jayanthi V, Probert CS, MacKay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8(12):1179-83.
6. Gifford AE, Berg AH, Lahiff C, Cheifetz AS, Horowitz G, Moss AC. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol. 2013;108(2):249-55.
7. Kane S, Becker B, Harmsen WS, Kurian A, Morisky DE, Zinsmeister AR. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012;107(2):154-60.
8. Lichtenstein GR, Rubin DT, Sabesin SM, Velayos FS, Vitat P. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Rev Gastroenterol Disord. 2008;8(1):21-30.
9. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577-85.
10. Kane SV. Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol (NY). 2007;3(10):795-99.
11. Bender BG, Rankin A, Tran ZV, Wamboldt FS. Brief-interval telephone surveys of medication adherence and asthma symptoms in the Childhood Asthma Management Program Continuation Study. Ann Allergy Asthma Immunol. 2008;101(4):382-86.
12. Cook PF, Emiliozzi S, El-Hajj D, McCabe MM. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns. 2010;81(2):182-86.
13. Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, Mayberry JF. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17(9):1874-81.
14. Moss AC, Chaudhary N, Tukey M, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis-a prospective study. J Crohns Colitis. 2010;4(2):171-75.
15. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA. 288(13):1594-1602.
16. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;16(2):CD000011.
17. Demonceau J, Ruppar T, Kristanto P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545-62.
18. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102(7):1417-26.
19. Yen L, Wu J, Hodgkins PL, Cohen RD, Nichol MB. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012;18(9):701-12. Available at: http://amcp.org/WorkArea/DownloadAsset.aspx?id=15874.
20. Wouters H, van Geffen EC, Baas-Thijssen MC, et al. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence. Breast. 2013;22(5):661-66.
21. Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13(10):1244-49.
22. Gray WN, Denson LA, Baldassano RN, Hommel KA. Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. J Pediatr Psychol. 2012;37(3):282-91.
23. Moshkovska T, Stone M, Baker R, Mayberry J. Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. Inflamm Bowel Dis. 2008;14(6):763-68.
24. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992;14(1):15-19.
25. Wolfe BJ, Sirois FM. Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease. Qual Life Res. 2008;17(6):877-86.
26. Chamberlain K, Camic P, Yardley L. Qualitative analysis of experience: grounded theory and case studies. In: Marks DF, Yardley L, eds. Research Methods for Clinical and Health Psychology. SAGE Publications, Thousand Oaks, CA; 2004:69-89.
27. Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269-81.
28. Lasch KE, Marquis P, Vigneux M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010;19(8):1087-96.
29. U.S. Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed November 11, 2013.
30. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266-71.
31. Gordon K, Smith F, Dhillon S. Effective chronic disease management: patients' perspectives on medication-related problems. Patient Educ Couns. 2007;65(3):407-15.
32. Vervloet M, Spreeuwenberg P, Bouvy ML, Heerdink ER, de Bakker DH, van Dijk L. Lazy Sunday afternoons: the negative impact of interruptions in patients' daily routine on adherence to oral antidiabetic medication: a multilevel analysis of electronic monitoring data. Eur J Clin Pharmacol. 2013;69(8):1599-606.
33. Vervloet M, van Dijk L, Santen-Reestman J, et al. SMS reminders improve adherence to oral medication in type 2 diabetes patients who are real time electronically monitored. Int J Med Inform. 2012;81(9):594-604.
34. Gifford A, Moss AC. Comment on Moshkovska et al. Inflamm Bowel Dis. 2013;19(2):E19.
35. Keith MD, Shimada SL, Rao SR, et al. Personal health record use and its association with antiretroviral adherence: survey and medical record data from 1,871 U.S. veterans infected with HIV. AIDS Behav. 2013;17(9):3091-100.
36. Acri T, TenHave TR, Chapman JC, Bogner HR, Gross R. Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. AIDS Behav. 2010;14(4):748-54.
37. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705.
38. Achleitner U, Coenen M, Colombel JF, Peyrin-Biroulet L, Sahakyan N, Cieza A. Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. J Crohns Colitis. 2012;6(5):507-17.